Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CD-001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CD (Suzhou) Biopharma Announces FDA Clearance for Phase I Clinical Trial of CD-001
Details : CD-001 is built on its BsFP platform. This potential therapy, designed to target PD-1 positive CD8+ T cells, aims to address unmet medical needs in oncology and viral infections.
Brand Name : CD-001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 20, 2024
Lead Product(s) : CD-001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?